冠昊生物
(300238)
| 流通市值：40.25亿 | | | 总市值：40.25亿 |
| 流通股本：2.65亿 | | | 总股本：2.65亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 293,480,433.06 | 200,869,647.98 | 94,797,135.39 | 377,483,103.8 |
| 营业收入 | 293,480,433.06 | 200,869,647.98 | 94,797,135.39 | 377,483,103.8 |
| 二、营业总成本 | 261,309,394.44 | 176,257,580.55 | 76,040,276.86 | 334,942,285.38 |
| 营业成本 | 65,461,131.78 | 44,086,491.08 | 21,756,284.1 | 77,525,843.69 |
| 税金及附加 | 4,370,483.24 | 2,983,951.39 | 1,086,779.49 | 5,256,670.06 |
| 销售费用 | 117,945,405.5 | 78,257,549.89 | 31,391,817.06 | 157,460,394.2 |
| 管理费用 | 44,580,466.84 | 30,605,219.15 | 13,010,932.5 | 57,170,350.92 |
| 研发费用 | 26,237,061.42 | 18,507,771.58 | 7,798,700.14 | 36,164,958.42 |
| 财务费用 | 2,714,845.66 | 1,816,597.46 | 995,763.57 | 1,364,068.09 |
| 其中:利息费用 | 2,805,431.95 | 1,937,900.01 | 1,022,766.68 | 1,030,373.62 |
| 其中:利息收入 | 460,993.41 | 334,875.48 | 187,266.08 | 665,099.62 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 191,885.2 | 143,125 | -120,731.4 | 606,241.58 |
| 资产处置收益 | -5,520.88 | -5,569.63 | -3,159.53 | 32,334.57 |
| 资产减值损失(新) | -1,576,829.59 | -1,362,152.32 | -20,090.05 | -17,072,238.17 |
| 信用减值损失(新) | -1,062,719.56 | -374,075.42 | -1,227,677.9 | -7,443,414.67 |
| 其他收益 | 1,723,707.23 | 966,649.78 | 463,223.77 | 9,579,849.74 |
| 四、营业利润 | 31,441,561.02 | 23,980,044.84 | 17,848,423.42 | 28,243,591.47 |
| 加:营业外收入 | 890,649.84 | 885,978.75 | 1,320,317.23 | 23,603.65 |
| 减:营业外支出 | 212,681.34 | 80,331.55 | 62,127.92 | 247,916.82 |
| 五、利润总额 | 32,119,529.52 | 24,785,692.04 | 19,106,612.73 | 28,019,278.3 |
| 减:所得税费用 | 11,690,361.99 | 8,272,801.87 | 4,378,826.18 | 11,411,784.85 |
| 六、净利润 | 20,429,167.53 | 16,512,890.17 | 14,727,786.55 | 16,607,493.45 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 20,429,167.53 | 16,512,890.07 | 14,727,786.55 | 16,607,493.45 |
| 终止经营净利润 | - | 0.1 | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 26,718,493.89 | 20,404,091.44 | 14,866,096.67 | 27,416,909.65 |
| 少数股东损益 | -6,289,326.36 | -3,891,201.27 | -138,310.12 | -10,809,416.2 |
| 扣除非经常损益后的净利润 | 25,820,574.06 | 19,803,890.16 | 13,865,743.31 | 19,714,325.01 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.1 | 0.08 | 0.06 | 0.1 |
| (二)稀释每股收益 | 0.1 | 0.08 | 0.06 | 0.1 |
| 八、其他综合收益 | -69,791.15 | -75,889.46 | -16,948.91 | 74,362.59 |
| 归属于母公司股东的其他综合收益 | -69,791.15 | -75,889.46 | -16,948.91 | 74,362.59 |
| 九、综合收益总额 | 20,359,376.38 | 16,437,000.71 | 14,710,837.64 | 16,681,856.04 |
| 归属于母公司股东的综合收益总额 | 26,648,702.74 | 20,328,201.98 | 14,849,147.76 | 27,491,272.24 |
| 归属于少数股东的综合收益总额 | -6,289,326.36 | -3,891,201.27 | -138,310.12 | -10,809,416.2 |
| 公告日期 | 2025-10-29 | 2025-08-28 | 2025-04-23 | 2025-04-23 |
| 审计意见(境内) | | | | 标准无保留意见 |